Course description
This 2.5-day symposium will provide up-to-date information to clinicians involved in the care of patients with breast or thoracic cancers. Speakers are nationally and internationally renowned clinicians and researchers who will share their expertise and foster discussion of the most recent multidisciplinary advances in screening, pathology, surgery, radiology, medical oncology, chemotherapy, immunotherapies, genetics and survivorship. Far-ranging areas of consensus and controversy will be presented and discussed with a goal that attendees leave with state-of-the-art knowledge of cancer care for breast and thoracic malignancies.

Learning objectives
Upon completion of this activity, attendees should be able to:

Thoracic portion (Thursday)
- Discuss the recent advances in thoracic surgery, radiation, and immunotherapy for treating lung cancer.
- Discuss the role for standard radiation and protons for thoracic malignancies disease.
- Review the choice of options for early stage lung cancer.
- Understand new options for small cell lung cancer.
- Discuss the most current systemic therapies for stage IV NSCLC.
- Review treatment options for thymic malignancies.
- Understand advances in multimodality therapy for pleural mesothelioma.
- Discuss value-based health care and the impact of payment reform.

Breast portion (Friday and half-day Saturday)
- Describe the pathogenesis, diagnostic evaluation and therapeutic advances for integration into the management of newly diagnosed breast cancer.
- Describe the therapeutic modalities available for advanced breast cancer, and neoadjuvant therapies in particular.
- Describe evidence-based recommendations for supportive care and survivorship.
- Describe how cancer outcomes can vary in different populations and potential reasons why.
- Discuss the impact of medical reform in the realm of oncology.
- Discuss how to manage patients at high risk for breast cancer, especially screening, prevention, and long-term surveillance.
- Navigate and interpret the plethora of available genetic tests and possible results.
- Discuss the ever-changing landscape of known genetic mutations.
- Illustrate the controversy regarding DCIS as a pathologic diagnosis and whether or not it requires local and/or systemic treatment.
- Discuss the role of reconstruction for patients in treatment as well as post-treatment.

CME/CE credit designation statement
The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Washington School of Medicine designates this live activity for a maximum of 17.0 PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider approved by the California Board of Registered Nursing, Provider #16496, for:
- 7.2 Contact Hours for the Thoracic Oncology portion
- 8.4 Contact Hours for the Breast Oncology portion

Registration fees

<table>
<thead>
<tr>
<th></th>
<th>Thoracic portion only (Thursday)</th>
<th>Breast portion only (Friday and half-day Saturday)</th>
<th>All Days</th>
</tr>
</thead>
<tbody>
<tr>
<td>MD / PhD</td>
<td>$300</td>
<td>$400</td>
<td>$525</td>
</tr>
<tr>
<td>UW / FH / SCCA Staff or SCCA Network Member*</td>
<td>$250</td>
<td>$350</td>
<td>$475</td>
</tr>
<tr>
<td>Allied Health Professionals (incl. NPs and PAs)</td>
<td>$225</td>
<td>$325</td>
<td>$425</td>
</tr>
<tr>
<td>Resident / Fellow</td>
<td>$200</td>
<td>$300</td>
<td>$400</td>
</tr>
<tr>
<td>UW Resident / UW Fellow</td>
<td>$175</td>
<td>$275</td>
<td>$375</td>
</tr>
</tbody>
</table>

The fee for this course includes catering, all instruction materials, and transcript of AMA PRA Category 1 Credits™. To ensure enrollment, please register online (see Registration). If you are an SCCA employee please email cme@seattlecca.org to register. If you have not received written confirmation prior to your departure for the course, contact the SCCA Strategic Outreach and Affiliate Network Office at (206) 288-1066. The SCCA Strategic Outreach and Affiliate Network Office will not be responsible for expenses incurred by an individual who is not confirmed and for whom space is not available at the course. If you have any additional questions, please contact the SCCA Strategic Outreach and Affiliate Network Office at sccanet@seattlecca.org or (206) 288-1066.

*SCCA Network Member rate is for employees of SCCA Network Members. For a full list of Network Members please visit SeattleCCA.org/network-members.cfm.

Intended audience
The course is designed for health care providers who treat patients with breast or thoracic cancer. Providers include surgeons, radiation, medical and surgical oncologists, pulmonologists, general practitioners, physicians assistants, oncology nurses, oncology pharmacists, fellows and other clinical trainees.

Additional course information
For information about online conference materials, the attendance policy, cancellation policy and special services, please visit the conference website. For the link to the conference website, please visit www.seattlecca.org/cme.

Conference location and lodging
The conference will be held in the heart of Seattle's vibrant downtown at the Sheraton Seattle Hotel: 1400 Sixth Ave., Seattle, WA 98101.

Regarding lodging, Seattle Cancer Care Alliance has not contracted for any special conference rates and accepts no responsibility for lodging. You may contact Sheraton.com for onsite lodging or visitseattle.org for lodging ideas in the area.

Thoracic Portion Co-Presented by the American Lung Association’s LUNG FORCE
See Page 8 for more information.

Register at SeattleCCA.org/cme
Course chairs

**Thoracic Oncology**
- Douglas Wood, MD, FACS, FRCSEd
  The Henry N. Harkins Professor and Chair of the Department of Surgery
- Renato Martins, MD, MPH
  Medical Director, Thoracic/Head and Neck Oncology
- Shilpen Patel, MD
  Associate Professor, Department of Radiation Oncology

**Breast Oncology**
- Kristine E Calhoun, MD
  Associate Professor, Department of Surgery
- Janice Kim, MD
  Associate Professor, Department of Radiation Oncology
- VK Gadi, MD, PhD, Chair Emeritus
  Associate Professor, Department of Oncology

For full listing of the course faculty and their titles, please visit the conference website.

Guest faculty

**Thoracic Oncology**
- Karen Reckamp, MD, MS
  Associate Professor, Medical Oncology, City of Hope, Duarte, CA
- Charles E. Leonard, MD
  Radiation Oncologist, Rocky Mountain Cancer Centers, Littleton, CO

**Breast Oncology**
- Anees B. Chagpar, MD, MBA, MPH, FACS, FRCS(C)
  Associate Professor of Surgery (Oncology); Assistant Director, Global Oncology, Yale Comprehensive Cancer Center, New Haven, CT

University of Washington, Fred Hutch and Seattle Cancer Care Alliance faculty

**Thoracic Oncology**
- Christina Baik, MD, MPH
- Kathleen Berfield, MD
- Laura QM Chow, MD
- Keith Eaton, MD, PhD
- Farhood Farjah, MD, MPH
- Bernardo Goulart, MD, MS
- Sylvia Lee, MD
- Mike Mulligan, MD
- Ramesh Rengan, MD, PhD
- Rafael Santana-Davila, MD

**Breast Oncology**
- Ben Anderson, MD
- Carol Baltaxe, PT, MPT, CLT
- Robin L. Bennett, MS, ScD Hon
- Denise Bundow, ARNP
- David Byrd, MD
- Jennie R Crews, MD, MMM
- Nancy E Davidson, MD
- Christine Fang, MD
- Laura James, ND
- Sara Javid, MD
- Mark Kilgore, MD
- Mary-Claire King, PhD
- Diana L Lam, MD
- Janie Lee, MD, MSc
- Hannah Linden, MD
- Barbara S Norquist, MD
- Savannah Partridge, PHD
- Hakim Said, MD
- John R Scheel, MD, PhD
- Veena Shankaran, MD, MS
- Janelle D Sousa, MD
- Beti Thompson, PhD
- Rachel Yung, MD

For full listing of the course faculty and their titles, please visit the conference website.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am</td>
<td>Breakfast, Registration and Exhibits Open</td>
<td>Kris Calhoun, MD</td>
</tr>
<tr>
<td>8:00 am</td>
<td>Welcome and Introductions</td>
<td>Kris Calhoun, MD</td>
</tr>
<tr>
<td>8:10 am</td>
<td>Case</td>
<td>Denise Bundow, ARNP</td>
</tr>
<tr>
<td>8:30 am</td>
<td>Breast cancer screening in high risk patients</td>
<td>Diana L Lam, MD</td>
</tr>
<tr>
<td>8:50 am</td>
<td>How to manage the plethora of new mutations</td>
<td>Robin Bennett, MS, LG, PhD Hon</td>
</tr>
<tr>
<td>9:10 am</td>
<td>Surgical options for gynecologic cancer prevention</td>
<td>Barbara S Norquist, MD</td>
</tr>
<tr>
<td>9:30 am</td>
<td>Tests out there</td>
<td>Mary-Claire King, PhD</td>
</tr>
<tr>
<td>10:10 am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:25 am</td>
<td>Surgery and radiation: yes</td>
<td>Anees Chagpar, MD, MBA, MPH</td>
</tr>
<tr>
<td>10:45 am</td>
<td>Surgery and radiation: no</td>
<td>Charles Leonard, MD</td>
</tr>
<tr>
<td>11:05 am</td>
<td>Rebuttal: surgery and radiation</td>
<td>All</td>
</tr>
<tr>
<td>11:25 am</td>
<td>Panel</td>
<td>All</td>
</tr>
<tr>
<td>11:45 am</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>12:45 pm</td>
<td>Financial toxicity in cancer care</td>
<td>Veena Shankaran, MD</td>
</tr>
<tr>
<td>1:05 pm</td>
<td>Medical reform in oncology</td>
<td>TBD</td>
</tr>
<tr>
<td>1:25 pm</td>
<td>Health reform: What happens when the ACA disappears?</td>
<td>Beti Thompson, PhD</td>
</tr>
<tr>
<td>1:45 pm</td>
<td>Health disparities in diverse populations</td>
<td>Hannah Linden, MD</td>
</tr>
<tr>
<td>2:05 pm</td>
<td>Panel</td>
<td>All</td>
</tr>
<tr>
<td>2:25 pm</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>2:40 pm</td>
<td>Case</td>
<td>Janie Lee, MD, MSc</td>
</tr>
<tr>
<td>2:50 pm</td>
<td>Pathology</td>
<td>Mark Kilgore, MD</td>
</tr>
<tr>
<td>3:10 pm</td>
<td>Imaging</td>
<td>Savannah Partridge, PhD</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Surgical: alliance trial</td>
<td>David Byrd, MD</td>
</tr>
<tr>
<td>3:50 pm</td>
<td>What to do with residual disease?</td>
<td>Nancy Davidson, MD</td>
</tr>
<tr>
<td>4:10 pm</td>
<td>Panel</td>
<td>All</td>
</tr>
<tr>
<td>4:30 pm</td>
<td>Closing; adjourn for the day</td>
<td>Kris Calhoun, MD</td>
</tr>
</tbody>
</table>

**Seattle Cancer Care Alliance** brings together the leading research teams and cancer specialists of Fred Hutch, Seattle Children’s, and UW Medicine. One extraordinary group whose sole mission is the pursuit of better, longer, richer lives for our patients.
The American Lung Association’s LUNG FORCE initiative has partnered with the Ad Council to launch the first national public service advertising (PSA) campaign focused on lung cancer screening.

Saved by the Scan aims to raise awareness of the benefits of early detection through lung cancer screening and drive individuals to take a lung cancer screening eligibility quiz at SavedByTheScan.org so that the approximately 9 million people in this country who are at high risk will talk to their doctor about getting screened for lung cancer.

The Thoracic portion is co-presented by American Lung Association’s LUNG FORCE

SavedByTheScan.org